Detection of binucleated nephrin-marked podocytes by flow cytometry in the urine of patients with obesity

Lioudaki E, Stylianou KG, Petrakis I, Kokologiannakis G, Passam A, Mikhailidis DP et al (2015) Increased urinary excretion of podocyte markers in normoalbuminuric patients with diabetes. Nephron 131(1):34–42 Yu D, Petermann A, Kunter U, Rong S, Shankland S, Floege J (2005) Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 16(6):1733–1741. https://doi.org/10.1681/ASN.2005020159 Pereira SV, Dos Santos M, Rodrigues PG, Do Nascimento JF, Timm JRT, Zancan R et al (2015) Increased urine podocyte-associated messenger RNAs in severe obesity are evidence of podocyte injury. Obesity 23(8):1643–1649 Suwanpen C, Nouanthong P, Jaruvongvanich V, Pongpirul K, Pongpirul WA, Leelahavanichkul A et al (2016) Urinary podocalyxin, the novel biomarker for detecting early renal change in obesity. J Nephrol 29(1):37–44 Zeng L, Szeto CC (2021) Urinary podocyte markers in kidney diseases. Vol. 523, Clinica Chimica Acta. Elsevier B.V., p. 315–24 Vogelmann SUS, Nelson WJ, Myers BD, Lemley KV (2003) Urinary excretion of viable podocytes in health and renal disease. Am J Physiol-Renal Physiol [Internet] 285(1):F40–48. Available from: http://www.ajprenal.org Larsen CP, Messias NC, Walker PD (2014) B7–1 immunostaining in proteinuric kidney disease. Am J Kidney Dis 64:1001–3 Lanzon B, Martin-Taboada M, Castro-Alves V, Vila-Bedmar R, González de Pablos I, Duberg D, Gomez P, Rodriguez E, Orešič M, Hyötyläinen T, Morales E, Ruperez FJ, Medina-Gomez G (2021) Lipidomic and metabolomic signature of progression of chronic kidney disease in patients with severe obesity. Metabolites 11(12):836. https://doi.org/10.3390/metabo11120836